Robert H. Hyland, DPhil

Gilead Sciences, Inc.

Poster(s):

• (506) Resistance Analyses from the Remdesivir Phase 3 REDPINE Study in Participants with Severely Reduced Kidney Function Who Were Hospitalized for COVID-19
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET

• (524) Hepatic Safety of Remdesivir Across Phase 3 Placebo-controlled COVID-19 Studies
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET

• (538) Clinical Evaluation of Drug-drug Interactions with Remdesivir
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET

• (539) Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir
  Thursday, October 12, 2023

  12:15 PM – 1:30 PM US ET